Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.…
Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering
Precision BioSciences (NASDAQ: DTIL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 69 employees.
The shares were at 7.400 USD on 20 November 2026, up 20.5% over 52 weeks. Its 52-week range is 3.530 USD to 11.29 USD: the price is 34.5% below the high and 109.6% above the low.
At a market capitalisation of 282.46M USD, it trades at 29.6 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 11% for DTIL.
Precision BioSciences reports return on equity of -49.6% and an operating margin of -80.3%.
It holds more cash than debt, a net cash position of 54.13M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 29.40 USD is 297.3% above the current price. The next earnings report is expected on 11 March 2027.